全文获取类型
收费全文 | 697篇 |
免费 | 39篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 19篇 |
妇产科学 | 16篇 |
基础医学 | 81篇 |
口腔科学 | 2篇 |
临床医学 | 50篇 |
内科学 | 176篇 |
皮肤病学 | 31篇 |
神经病学 | 44篇 |
特种医学 | 13篇 |
外科学 | 106篇 |
综合类 | 6篇 |
预防医学 | 134篇 |
眼科学 | 14篇 |
药学 | 23篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 3篇 |
2022年 | 19篇 |
2021年 | 23篇 |
2020年 | 12篇 |
2019年 | 29篇 |
2018年 | 24篇 |
2017年 | 17篇 |
2016年 | 26篇 |
2015年 | 18篇 |
2014年 | 40篇 |
2013年 | 33篇 |
2012年 | 47篇 |
2011年 | 66篇 |
2010年 | 40篇 |
2009年 | 29篇 |
2008年 | 45篇 |
2007年 | 36篇 |
2006年 | 39篇 |
2005年 | 28篇 |
2004年 | 28篇 |
2003年 | 32篇 |
2002年 | 23篇 |
2001年 | 14篇 |
2000年 | 13篇 |
1999年 | 9篇 |
1998年 | 4篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1985年 | 6篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1975年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有741条查询结果,搜索用时 15 毫秒
61.
Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment 总被引:2,自引:0,他引:2
Elloumi H Houissa F Hadj NB Gargouri D Romani M Kharrat J Ghorbel A 《World journal of gastroenterology : WJG》2007,13(40):5411-5412
Adverse effects associated with peginterferon and ribavirin during hepatitis C treatment are well known. Sudden hearing loss has rarely been reported. Possible mechanisms involved include direct ototoxicity of interferon, autoimmunity, and hematological changes. Hearing loss is frequently fully resolved after discontinuation of antiviral therapy. We report a 47-year- old man with chronic hepatitis C, genotype 2 ac who developed sudden hearing loss 22 wk after starting therapy with peginterferon alpha 2a at a dose of 180 ~g per week and ribavirin 800 mg per day. Since symptoms did not worsen, antiviral therapy was continued for 2 wk, according to the patient's wish. Hearing loss resolved within 2 wk after the end of treatment. Serum liver alanine aminotransferase remained normal during and after the end of antiviral therapy. HCV RNA was undetectable at the end of therapy and remained negative 24 wk later. Thus, patients should be aware that hearing loss may occur with peginterferon therapy, but the decision whether to continue or to stop the treatment is based on the clinical judgment of the physician and the wishes of the patient. 相似文献
62.
Julien Doyon Maria Korman Amélie Morin Valérie Dostie Abdallah Hadj Tahar Habib Benali Avi Karni Leslie G. Ungerleider Julie Carrier 《Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale》2009,195(1):15-26
There is increasing evidence supporting the notion that the contribution of sleep to consolidation of motor skills depends
on the nature of the task used in practice. We compared the role of three post-training conditions in the expression of delayed
gains on two different motor skill learning tasks: finger tapping sequence learning (FTSL) and visuomotor adaptation (VMA).
Subjects in the DaySleep and ImmDaySleep conditions were trained in the morning and at noon, respectively, afforded a 90-min nap early in the afternoon and were re-tested
12 h post-training. In the NightSleep condition, subjects were trained in the evening on either of the two learning paradigms and re-tested 12 h later following
sleep, while subjects in the NoSleep condition underwent their training session in the morning and were re-tested 12 h later without any intervening sleep. The
results of the FTSL task revealed that post-training sleep (day-time nap or night-time sleep) significantly promoted the expression
of delayed gains at 12 h post-training, especially if sleep was afforded immediately after training. In the VMA task, however,
there were no significant differences in the gains expressed at 12 h post-training in the three conditions. These findings
suggest that “off-line” performance gains reflecting consolidation processes in the FTSL task benefit from sleep, even a short
nap, while the simple passage of time is as effective as time in sleep for consolidation of VMA to occur. They also imply
that procedural memory consolidation processes differ depending on the nature of task demands.
J. Doyon and M. Korman contributed equally. 相似文献
63.
Despite the lack of effective vaccines against parasitic diseases, the prospects of developing a vaccine against leishmaniasis are still high. With this objective, we have tested four DNA based candidate vaccines encoding to immunodominant leishmania antigens (LACKp24, TSA, LmSTI1 and CPa). These candidates have been previously reported as capable of eliciting at least partial protections in the BALB/c mice model of experimental cutaneous leishmaniasis. When tested under similar experimental conditions, all of them were able to induce similar partial protective effects, but none could induce a full protection. In order to improve the level of protection we have explored the approach of DNA based vaccination with different cocktails of plasmids encoding to the different immunodominant Leishmania antigens. A substantial increase of protection was achieved when the cocktail is composed of all of the four antigens; however, no full protection was achieved when mice were challenged with a high dose of parasite in their hind footpad. The full protection was only achieved after a challenge with a low parasitic dose in the dermis of the ear. It was difficult to determine clear protection correlates, other than the mixture of immunogens induced specific Th1 immune responses against each component. Therefore, such an association of antigens increased the number of targeted epitopes by the immune system with the prospects that the responses are at least additive if not synergistic. Even though, any extrapolation of this approach when applied to other animal or human models is rather hazardous, it undoubtedly increases the hopes of developing an effective leishmania vaccine. 相似文献
64.
Diane Pourchot M.D. Christine Bodemer M.D. Ph.D. Alice Phan M.D. Ph.D. Anne‐Claire Bursztejn M.D. Ph.D. Smaïl Hadj‐Rabia M.D. Ph.D. Franck Boralevi M.D. Ph.D. Juliette Miquel M.D. Thomas Hubiche M.D. Eve Puzenat M.D. Anne‐Laure Souillet M.D. Ingrid Kupfer M.D. Maryam Piram M.D. Alain Beauchet M.D. Emmanuel Mahé M.D. Groupe de Recherche de la Société Française de Dermatologie Pédiatrique 《Pediatric dermatology》2017,34(1):58-63
65.
R. Amode S. Hadj‐Rabia A.‐C. Bursztejn A. Phan F. Boralevi C. Droitcourt J. Mazereeuw‐Hautier M. Piram P. Plantin C. Absaq A. Lasek‐Duriez X. Balguierie A. Maruani A. Beauchet E. Mahé the Groupe de Recherche de la Société Française de Dermatologie Pédiatrique 《Journal of the European Academy of Dermatology and Venereology》2016,30(8):1390-1392
66.
67.
68.
Samadi P Morissette M Calon F Hadj Tahar A Dridi M Belanger N Meltzer LT Bédard PJ Di Paolo T 《Synapse (New York, N.Y.)》2008,62(2):101-109
L-Dopa therapy in Parkinson's disease (PD) is counfounded by the development of involuntary movements such as L-Dopa-induced dyskinesias (LIDs). In this study GABA(A) receptor autoradiography was assessed using [(3)H]flunitrazepam binding to the benzodiazepine site of the GABA(A) receptor and [(35)S]t-butylbicyclophosphorothionate (TBPS) binding to the chloride channel of GABA(A) receptors in the substantia nigra reticulata (SNr) and subthalamic nucleus (STN). L-Dopa-treated parkinsonian monkeys experiencing LIDs were compared to animals in which LIDs was prevented by adjunct treatments with CI-1041, a selective antagonist of the NR1A/2B subtype of NMDA receptor, or low doses of the dopamine D2 receptor agonist, cabergoline. Our results demonstrated a decrease of GABA(A) receptor specific binding in the posterior part of the SNr in dyskinetic monkeys compared to nondyskinetic animals, while no modulation has been observed in the STN. These results provide evidence for the first time that pharmacological treatments preventing LIDs in nonhuman primate model of PD are associated with normalization of GABA(A) receptor-mediated signalling in the SNr. 相似文献
69.
U. Ordioni M. Hadj Saïd G. Thiery F. Campana J.-H. Catherine R. Lan 《International journal of oral and maxillofacial surgery》2019,48(1):28-39
The aim of this study was to perform a critical review of published data on the epidemiological, aetiological, clinical, histological, biological, and therapeutic characteristics of patients with angina bullosa haemorrhagica (ABH). A literature search was conducted in the PubMed, Science Direct, Web of Science, and Cochrane Library databases. All publications fulfilling the selection criteria were included in the eligibility assessment according to the PRISMA statement. The full texts of 54 retrieved articles were screened. Forty articles published between 1985 and 2016 describing 225 cases of ABH were finally selected. The mean age of the patients was 55.4 years; the male to female ratio was 0.7. The predominant localization was the palate (66%). A third of patients had no medical history. When specified, a triggering event or promoting factor was frequently found (82%). Biological tests were normal. A biopsy was performed on 35% of the patients. Treatment was symptomatic with a favourable outcome. Recurrences were frequent (62%). In conclusion, ABH is poorly documented and only by studies of low-level evidence. This review did not allow any aetiopathogenic association to be made with a general pathology or treatment. On the basis of this systematic review of the literature, diagnostic criteria aiming to improve the care of patients presenting with ABH are proposed. 相似文献
70.
Phlegmesia cerulea dolens (PCD) is a rare complication of deep vein thrombosis characterized by massive venous thrombosis leading to arterial compromise and tissue ischaemia. PCD carries high morbidity and mortality and is an often times overlooked cause of acute limb ischaemia that must be recognized and treated promptly. Early referral for percutaneous catheter directed thrombectomy offers an alternative to thrombolysis in patients who present with venous gangrene or fail anticoagulation therapy. A case of PCD is presented in a 71‐year‐old woman with end‐stage renal disease 3 days after right femoral dialysis catheter placement. 相似文献